What is the bonus history of the Aarey Drugs?

Aarey Drugs & Pharmaceuticals Ltd issued a 1:5 bonus on June 25, 2012, granting shareholders one additional share for every five shares held, with a record date of June 26, 2012. This is the company's most recent bonus action.

Aarey Drugs & Pharmaceuticals Ltd has a bonus history that includes a notable issue on June 25, 2012. The company announced a 1:5 bonus issue, meaning that for every five shares held, shareholders received one additional share. The record date for this bonus was June 26, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Aarey Drugs or need further details, feel free to ask!

Has Aarey Drugs declared dividend?

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend, amounting to ₹0.10 per share, with an ex-date of December 13, 2018. Despite the dividend declaration, the dividend yield is 0%, and total returns over various periods show significant price appreciation, especially over five years.

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.10<BR>- Ex-date: 13 Dec 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -12.92%, the dividend return was 0%, resulting in a total return of -12.92%.<BR><BR>For the 1 year period, the price return was 21.16%, the dividend return was 0%, leading to a total return of 21.16%.<BR><BR>Over the 2 years period, the price return was 66.72%, the dividend return was 0%, culminating in a total return of 66.72%.<BR><BR>In the 3 years period, the price return was 50.85%, the dividend return was 0%, which resulted in a total return of 50.85%.<BR><BR>For the 4 years period, the price return was 55.93%, the dividend return was 0%, yielding a total return of 55.93%.<BR><BR>In the 5 years period, the price return was 155.4%, the dividend return was 0%, resulting in a total return of 155.4%.<BR><BR>Overall, Aarey Drugs has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with significant price returns in the longer term, particularly over 5 years.

Who are the peers of the Aarey Drugs?

Aarey Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, BDH Industries, Denis Chem Lab, and Tyche Industries. Aarey Drugs has average management risk and below average growth and capital structure compared to its peers, with a 1-year return of 13.67%.

Peers: The peers of Aarey Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, BDH Industries, Denis Chem Lab, Tyche Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Tyche Industries, and the rest. Average management risk is found at Aarey Drugs and Denis Chem Lab. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen in Divi's Lab., Torrent Pharma, Smruthi Organic, BDH Industries, Aarey Drugs, Denis Chem Lab, and Tyche Industries. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Smruthi Organic, BDH Industries, and Tyche Industries, while Aarey Drugs has a below average capital structure along with Denis Chem Lab.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Denis Chem Lab has the lowest at -38.43%. Aarey Drugs' 1-year return of 13.67% is higher than Denis Chem Lab's but lower than Divi's Lab.'s. Additionally, the six-month return is negative for BDH Industries, Denis Chem Lab, and Tyche Industries.

What is the technical trend for Aarey Drugs?

As of June 5, 2025, Aarey Drugs shows a neutral technical stance with mixed signals: weekly indicators are bullish while daily trends are mildly bearish, suggesting caution despite potential upward movement indicated by Bollinger Bands.

As of 5 June 2025, the technical trend for Aarey Drugs has changed from mildly bearish to sideways. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds caution. The KST shows a bullish stance weekly but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with a mildly bullish monthly outlook. Overall, the current technical stance is neutral, with strength in the weekly indicators but caution from daily trends.

Who are in the management team of Aarey Drugs?

As of March 2023, the management team of Aarey Drugs includes Mihir R Ghatalia (Chairman & Managing Director), Nimit R Ghatalia (Executive Director), and several independent directors: Chetan K Mehta, Lalit Tulsiani, and Anil Mandal, along with Preeti Paresh Rathi (Company Secretary) and Bina Ghatalia (Additional Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Aarey Drugs includes the following individuals:<BR><BR>1. Mihir R Ghatalia - Chairman & Managing Director<BR>2. Chetan K Mehta - Independent Director<BR>3. Preeti Paresh Rathi - Company Secretary & Compliance Officer<BR>4. Lalit Tulsiani - Independent Director<BR>5. Nimit R Ghatalia - Executive Director<BR>6. Anil Mandal - Independent Director<BR>7. Bina Ghatalia - Additional Director<BR><BR>Each member plays a distinct role within the company, contributing to its governance and operations.

What does Aarey Drugs do?

Aarey Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with net sales of 1,081 Cr and a net profit of 5 Cr as of March 2025. Originally incorporated as Niharika Textiles in 1990, it became a public company in 1993 under the Aarey Group.

Overview: <BR>Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated in 1990 as Niharika Textiles & Chemicals Pvt Ltd. It underwent a status change to a public limited company in March 1993 after being taken over by the Aarey Group of companies. The latest reported quarter for sales and profit is March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,081 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 195 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 47.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.24 <BR>Return on Equity: 2.91% <BR>Price to Book: 1.41 <BR><BR>Contact Details: <BR>Address: E-34 MIDC Tarapur, Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-23455543 <BR>Website: http://www.aareydrugs.com

Who are the top shareholders of the Aarey Drugs?

The top shareholders of Aarey Drugs include promoter Bina Rajesh Ghatalia with 14.12%, and the highest public shareholder, India Opportunities Growth Fund Ltd - Pinewood, with 2.34%. Individual investors hold 45.79%, and there is one foreign institutional investor with 2.34%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Aarey Drugs include Bina Rajesh Ghatalia, who is the promoter with the highest holding at 14.12%. Additionally, the highest public shareholder is India Opportunities Growth Fund Ltd - Pinewood, holding 2.34%. The company also has individual investors holding a significant portion at 45.79%. Furthermore, there is one foreign institutional investor (FII) that holds 2.34% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Aarey Drugs?

As of 24th July, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 192.00 Cr, with recent net sales of 473.94 Cr and a net profit of 4.03 Cr. The balance sheet for March 2024 shows shareholder's funds of 132.77 Cr and total assets of 303.29 Cr.

As of 24th July, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 192.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Aarey Drugs reported Net Sales of 473.94 Cr and a Net Profit of 4.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 132.77 Cr and Total Assets of 303.29 Cr.

Are Aarey Drugs latest results good or bad?

Aarey Drugs reported a challenging quarter ending June 2025, with a 45.72% decline in Profit After Tax and a 19.46% drop in net sales, marking the lowest sales in five quarters. Despite improved debt collection efficiency, the high reliance on non-operating income and negative market sentiment indicate a difficult financial outlook.

Aarey Drugs & Pharmaceuticals has reported a challenging performance for the quarter ending June 2025. The company experienced a significant decline in its Profit After Tax (PAT), which stands at Rs 1.84 crore, down 45.72% year-on-year. Additionally, net sales fell to Rs 102.21 crore, reflecting a decrease of 19.46% compared to the same period last year, marking the lowest sales recorded in the last five quarters.<BR><BR>While there is a positive aspect regarding the company's Debtors Turnover Ratio, which improved to 3.66 times for the half-yearly period, indicating better efficiency in settling debts, the overall financial landscape remains concerning. A high percentage of non-operating income, comprising 89.60% of Profit Before Tax (PBT), raises questions about the sustainability of the business model.<BR><BR>Market sentiment is also unfavorable, as reflected in the stock being rated as a 'Sell' by MarketsMOJO. Overall, the results suggest a difficult period for Aarey Drugs, with significant declines in key financial metrics.

When is the next results date for Aarey Drugs?

Aarey Drugs will announce its results on 13 November 2025.

Aarey Drugs is scheduled to declare its results on 13 November 2025.

Is Aarey Drugs overvalued or undervalued?

As of November 17, 2025, Aarey Drugs is considered overvalued with a high PE ratio of 75.88, weak profitability indicated by a 2.47% ROE, and negative operational metrics, despite recent strong stock performance.

As of 17 November 2025, Aarey Drugs has moved from a fair to a risky valuation grade. The company appears to be overvalued, primarily indicated by its high PE ratio of 75.88 and an EV to EBITDA ratio of 134.14, which are significantly above industry norms. Additionally, the return on equity (ROE) stands at a mere 2.47%, reflecting weak profitability, while the EV to EBIT ratio is notably negative at -315.22, suggesting severe operational challenges.<BR><BR>In comparison to its peers, Aarey Drugs' valuation metrics are concerning. For instance, Elitecon International has a PE ratio of 294.38, indicating a very expensive valuation, while PTC India, which is considered very attractive, has a PE of just 7.56. Aarey Drugs' high valuation ratios, combined with its negative ROCE of -0.07%, further underscore its overvaluation status. Despite recent strong stock performance against the Sensex, with a year-to-date return of 68.93% compared to the Sensex's 8.72%, the underlying financial metrics suggest that the stock may not sustain its current price levels.

How has been the historical performance of Aarey Drugs?

Aarey Drugs has experienced fluctuating financial performance, with net sales increasing to 473.94 Cr in March 2025 from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. Profitability metrics, including operating profit and earnings per share, have generally declined, indicating challenges in maintaining consistent profitability.

Answer:<BR>The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profitability over the years, with net sales reaching 473.94 Cr in March 2025, up from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. The total operating income followed a similar pattern, peaking at 492.68 Cr in March 2022 before declining to 473.94 Cr in March 2025. The operating profit (PBDIT) has also seen a decline, from 14.02 Cr in March 2022 to 12.70 Cr in March 2025. Profit before tax increased slightly to 6.10 Cr in March 2025 from 5.34 Cr in March 2024, while profit after tax decreased to 4.02 Cr in March 2025 from 4.68 Cr in March 2024. The company's earnings per share (EPS) dropped to 1.43 in March 2025 from 1.67 in March 2024, reflecting the overall decline in profitability.<BR><BR>Breakdown:<BR>Aarey Drugs' financial performance has shown variability in key metrics over the years. Net sales increased from 395.62 Cr in March 2024 to 473.94 Cr in March 2025, although this is a decrease from the 492.68 Cr recorded in March 2022. Total operating income mirrored this trend, with a peak in March 2022 before falling to 473.94 Cr in March 2025. Operating profit (PBDIT) has declined from 14.02 Cr in March 2022 to 12.70 Cr in March 2025, indicating a downward trend in profitability. Profit before tax saw a slight increase to 6.10 Cr in March 2025, while profit after tax decreased to 4.02 Cr in the same period. The earnings per share (EPS) also fell to 1.43 in March 2025 from 1.67 in March 2024, reflecting the challenges faced by the company in maintaining profitability amidst fluctuating sales and operating income.

Should I buy, sell or hold Aarey Drugs?

Which are the latest news on Aarey Drugs?

Why is Aarey Drugs falling/rising?

As of 04-Dec, Aarey Drugs & Pharmaceuticals Ltd's stock price is currently at 80.69, reflecting a recent upward trend after two days of decline, despite a significant drop in investor participation. The stock has shown strong year-to-date performance with a 42.29% gain, although it has experienced declines over the past week and month.

As of 04-Dec, Aarey Drugs & Pharmaceuticals Ltd's stock price is rising, currently at 80.69, reflecting an increase of 0.98 (1.23%). This upward movement comes after a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 1.21% today. <BR><BR>Despite a recent decline over the past week and month, where the stock fell by 9.87% and 17.80% respectively, it has shown strong performance year-to-date with a gain of 42.29%. The stock's performance over the last three years has also been robust, with a 101.72% increase, indicating a long-term positive trend.<BR><BR>However, it is important to note that there has been a significant drop in investor participation, with delivery volume on 03 Dec falling by 99.65% compared to the 5-day average. This decline in trading activity could suggest caution among investors. Nevertheless, the current price movement indicates a positive shift, supported by the stock's performance relative to its sector and its position above longer-term moving averages.